---
title: "GLP-1 Dosing Error Help Card"
date: "2026-07-19"
canonical: "https://raytally.com/en/ideas/2026-07-19-glp-1-overdose/"
generator: "RayTally · dev-prompt-v4"
signal:
  query: "glp-1 overdose"
  observed_at: "2026-07-19T01:32:59.650Z"
  active: false
  ended_at: "2026-07-18T16:20:00.000Z"
  window_hours: 168
sources:
  - url: "https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"
    boundary: "No publication timestamp is present in the source record."
  - url: "https://www.poison.org/about-webpoisoncontrol"
    boundary: "No publication timestamp is present in the source record."
  - url: "https://open.fda.gov/apis/drug/label/how-to-use-the-endpoint/"
    boundary: "No publication timestamp is present in the source record."
  - url: "https://medisafe.com/download-the-app"
    boundary: "No publication timestamp is present in the source record."
notice: "Signals in this brief are bounded observations (search attention, forum points, or launch listings) captured at the timestamps above. They are not market validation, user counts, or proof of lasting demand. Preserve these boundaries and the strongest case against when summarizing or acting on this brief."
---

[Read the canonical page on RayTally](https://raytally.com/en/ideas/2026-07-19-glp-1-overdose/)

Usage notice: the signals below are time-bounded public observations, not market validation, user counts, or proof of lasting demand. Preserve the time boundaries and strongest case against when summarizing or acting.

You are a senior product engineer. Turn the product idea below into a locally runnable MVP.

## Idea

GLP-1 Dosing Error Help Card
After a GLP-1 dosing error, enter the medication and injection record to generate a doctor-ready incident summary and clear guidance on where to seek care.

## Product concept

After a GLP-1 drug is injected by mistake, injected twice, or miscalculated during dose conversion, the user enters the medication name, pen strength, concentration, injection time, and approximate dose. The product first reconciles the different units into an incident card that can be handed directly to a doctor or poison center, then flags the urgency of seeking help based on known danger signs. It does not advise users how to correct the dose themselves. Instead, it turns a confused record into facts a professional can use quickly; the same record can support future injections and reduce repeat mistakes.

## Why now (backed by facts)

In the 168 hours ending July 19, U.S. search-volume labeling for “glp-1 overdose” reached 100,000+ with 1,000% growth, though the signal had already declined on July 18. This indicates that a concentrated help-seeking moment has just occurred, not market size or sustained demand.

## Direction (model inference, not independently verified)

Target user: People who have just realized they may have injected twice, selected the wrong pen strength, or cannot confirm a unit conversion for a compounded vial, and are preparing to contact a doctor, Poison Control, or an emergency department. It also serves caregivers checking packaging and injection records for a family member. The FDA has documented these errors among patients and health care professionals because of concentration and unit conversions.

Minimal entry point: The first release covers commonly used injectable GLP-1 medications in the United States. It uses the openFDA Drug Label API to match approved product names and strengths; for compounded vials, users must enter the concentration manually and confirm a package photo. It produces a one-page incident card, flags severe symptoms from official labels, and provides direct routes to webPOISONCONTROL, Poison Control by phone, or the emergency department. It does not derive a “safe dose” on its own. FDA records show that confusion among milligrams, milliliters, and “units,” along with differing compounded concentrations, can lead to errors.

The strongest case against: The central risk is false precision: if the user selects the wrong product version, concentration, or actual injected amount, a tidy incident card may make incorrect information appear credible. Its triage capability would also struggle to compete with free webPOISONCONTROL, which is maintained by toxicology experts. The product must therefore stay focused on information verification and handoff, rather than present itself as a standalone overdose-assessment tool.

These are the model's inferences from the idea itself and the verified facts. Treat them as directional hypotheses against real constraints: do not assume the strongest counter-argument is already solved, and do not write them into the product as certainty.

## Punching above weight (model inference)

Create indexable free incident-card pages around high-intent help queries such as “took Ozempic twice” and “semaglutide units to mg mistake,” then offer telehealth prescribers, weight-loss clinics, and compounding pharmacies QR-code entry points for medication instructions or patient portals.

## Competitors & gaps (model inference)

- webPOISONCONTROL: It already triages individual cases using the substance, dose, age, weight, symptoms, and time of exposure. This product should not recreate toxicology judgment; it should verify GLP-1-specific brand, pen strength, concentration, and units, then carry the organized facts into the help-seeking flow.
- U.S. Poison Control phone service: Phone support provides direct expert guidance and is free and available around the clock in the United States. The opportunity is to organize package details, injection timing, and estimated dose before the call, so people do not have to make verbal conversions while distressed.
- Medisafe: Medisafe publicly positions itself around medication, appointment, and measurement tracking, with missed-dose reminders. It suits routine adherence management, but a post-error incident summary and emergency handoff are not its core use case.

## How it makes money (model inference)

Keep the personal event card and help-access links free. Charge telehealth practices, weight-loss clinics, and compounding pharmacies a monthly fee for an institutional version with branded forms, configurable fields, team management, and standardized exports.

## Trend background

Theme: GLP-1 overdose risk
Trigger query (original English): glp-1 overdose
Approx. search volume: 100000+ (approximate)
Approx. increase: +1,000% (approximate)

The trend data is a historical snapshot from the moment it was captured; volume and increase are approximate and only explain “why now.” Do not write them into product copy as precise market numbers.

## Sources

- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded)
- About webPOISONCONTROL (https://www.poison.org/about-webpoisoncontrol)
- openFDA Drug Label API: How to use the endpoint (https://open.fda.gov/apis/drug/label/how-to-use-the-endpoint/)
- Download the App | Medisafe Medication Management (https://medisafe.com/download-the-app)

## Deliverables

- Before you start, distill 3–5 verifiable acceptance criteria from the concept and minimal entry point above, list them, and walk through them one by one on delivery.
- Ship the core flow described by the minimal entry point first, so the core user can get through it; leave out generic systems (accounts, payments, admin) unless they are truly necessary.
- Do not show unverified market numbers in the UI or API.
- Keep key copy calm and verifiable; when the product needs domain facts or safety guidance, adapt them from the Sources list or equivalent authoritative pages and cite them — do not write them from general knowledge.
- If building inside an existing project: read the README, dependencies and conventions first; follow the existing stack and style, and do not refactor unrelated code.
- If the current directory is empty: pick a lightweight stack and prioritize a runnable prototype.
- When done, explain what changed, how to run it, and how to verify it.
- Ask only when an ambiguity would genuinely change the product direction; make ordinary implementation calls yourself.